A citation-based method for searching scientific literature

R Peto, C Davies, J Godwin, R Gray, H C Pan, M Clarke, D Cutter, S Darby, P McGale, C Taylor, Y C Wang, J Bergh, A Di Leo, K Albain, S Swain, M Piccart, K Pritchard. Lancet 2012
Times Cited: 1260



Ivana Sestak, Richard Buus, Jack Cuzick, Peter Dubsky, Ralf Kronenwett, Carsten Denkert, Sean Ferree, Dennis Sgroi, Catherine Schnabel, Frederick L Baehner, Elizabeth Mallon, Mitch Dowsett. JAMA Oncol 2018
Times Cited: 162




List of shared articles



Times cited

How we treat HR-positive, HER2-negative early breast cancer.
Sara Lopez-Tarruella, Isabel Echavarria, Yolanda Jerez, Blanca Herrero, Salvador Gamez, Miguel Martin. Future Oncol 2022
0

Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?
Stefania Morganti, Antonio Marra, Edoardo Crimini, Paolo D'Amico, Paola Zagami, Giuseppe Curigliano. Breast Cancer Res Treat 2022
0

Population-based estimates of overtreatment with adjuvant systemic therapy in early breast cancer patients with data from the Netherlands and the USA.
M A A Ragusi, B H M van der Velden, M C van Maaren, E van der Wall, C H van Gils, R M Pijnappel, K G A Gilhuijs, S G Elias. Breast Cancer Res Treat 2022
0

Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline.
Phillip Blanchette, Duvaraga Sivajohanathan, John Bartlett, Andrea Eisen, Harriet Feilotter, Rossanna Pezo, Gulisa Turashvili, Phillip Williams. Curr Oncol 2022
0

Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy.
Salvatore Pece, Ivana Sestak, Francesca Montani, Micol Tillhon, Patrick Maisonneuve, Stefano Freddi, Kim Chu, Marco Colleoni, Paolo Veronesi, Davide Disalvatore,[...]. Eur J Cancer 2022
0

Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer.
Alexios Matikas, Athanasios Kotsakis, Stella Apostolaki, Helen Politaki, Maria Perraki, Kostas Kalbakis, Michalis Nikolaou, Panagiota Economopoulou, Dora Hatzidaki, Vassilis Georgoulias. Br J Cancer 2022
3

Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review.
Mattia Garutti, Gaia Griguolo, Andrea Botticelli, Giulia Buzzatti, Carmine De Angelis, Lorenzo Gerratana, Chiara Molinelli, Vincenzo Adamo, Giampaolo Bianchini, Laura Biganzoli,[...]. Cancers (Basel) 2022
0

The IHC4+C score: an affordable and reproducible non-molecular decision-aid in hormone receptor-positive breast cancer. Does it still hold value for patients in 2020?
Nadav Harel, Steven Cheema, David Williams, Kerryn Ireland-Jenkin, Tineke Fancourt, Andrew Dodson, Belinda Yeo. Asia Pac J Clin Oncol 2021
0

Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative.
Paolo Giorgi Rossi, Annette Lebeau, Carlos Canelo-Aybar, Zuleika Saz-Parkinson, Cecily Quinn, Miranda Langendam, Helen Mcgarrigle, Sue Warman, David Rigau, Pablo Alonso-Coello,[...]. Br J Cancer 2021
3